MedPath

BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnoea (BLAST OSA)

Not Applicable
Completed
Conditions
Obstructive Sleep Apnea of Adult
Registration Number
NCT03048604
Lead Sponsor
Nyxoah S.A.
Brief Summary

The study is designed as a prospective, open-label, multicentre, non-randomized, single arm treatment study to assess the safety, performance and initial efficacy trends of the GenioTM System in patients with Obstructive Sleep Apnoea (OSA).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
27
Inclusion Criteria
  • Body mass index ≤32 kg/m2
  • Patients who do not tolerate or do not accept positive airway pressure (PAP) treatments.
  • Obstructive apnoea-hypopnea index (AHI) of 20-60 events/hour

Main

Exclusion Criteria
  • Unable or incapable of providing informed written consent
  • Unwilling or incapable of returning to all follow-up visits and sleep studies, including evaluation procedures and filling out questionnaires
  • Significant co-morbidities making the patient unable or inappropriate to participate in the trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Performance6-months post implantation

Change from baseline to 6-month post implantation in the apnoea-hypopnea index (AHI)

Safety (Incidence of serious device-related adverse events)6-months post implantation

Incidence of serious device-related adverse events

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Hollywood Private UWA Centre for Sleep Science Facility

🇦🇺

Nedlands, Perth, Australia

La Pitié Salpêtrière - Paris

🇫🇷

Paris, France

Royal National Throat, Nose and Ear Hospital - London

🇬🇧

London, United Kingdom

Hollywood Private UWA Centre for Sleep Science Facility
🇦🇺Nedlands, Perth, Australia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.